Merck News
Most Popular Merck Story
AZ to pay $647M for Merck rights
AstraZeneca has exercised its option to buy out Merck's interest in some of its products, planning to pay its U.S. rival $647 million for its share of blood pressure drugs Atacand, Lexxel and... Read more...
Latest Headlines
- March 15, 2010
- March 9, 2010
- March 5, 2010
- March 3, 2010
- March 1, 2010
- February 17, 2010
- February 17, 2010
- February 16, 2010
- February 12, 2010
- February 10, 2010
- February 10, 2010
- February 8, 2010
- February 4, 2010
- January 29, 2010
- January 27, 2010
- January 26, 2010
- January 14, 2010
- January 13, 2010
- January 8, 2010
- January 7, 2010
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
